Daiichi Sankyo

AstraZeneca, Daiichi Sankyo launch reflux esophagitis iPhone app

Wednesday, September 18, 2013 01:36 PM

Daiichi Sankyo and AstraZeneca are working to educate the public about reflux esophagitis through a campaign entitled Do you experience heartburn or acid reflux? The awareness building effort seeks to ensure an accurate understanding of the symptoms of reflux esophagitis and how they affect the daily lives of patients. The campaign incorporates a variety of media, featuring TV commercials, an iPhone app and a website to encourage patients to seek the appropriate treatment and take control of their lives.

More... »

Daiichi Sankyo extends Medidata use to China

Monday, August 5, 2013 11:53 AM

Japan-based pharmaceutical company Daiichi Sankyo is expanding its use of Medidata Solutions' cloud-based platform to support clinical trials conducted by its division in China, an investment expected to streamline trial activities, improve the efficiency of data capture and increase the productivity of site users and clinical monitors. Daiichi Sankyo will bring Medidata's applications for electronic data capture, clinical data management and randomization and trial supply management to its expanding clinical work in China.

More... »

Japan screening massive drug compound libraries for new treatments

Wednesday, June 5, 2013 01:32 PM

The Global Health Innovative Technology Fund (GHIT Fund), a public-private partnership focused on Japanese R&D related to infectious disease, will make a series of agreements to screen compound libraries at Japanese pharmaceutical companies and research institutes for new treatments for malaria, tuberculosis and other afflictions.

More... »

Japan establishes global fund for R&D of new medicines, vaccines, diagnostics

Wednesday, April 10, 2013 10:15 AM

Japan’s first public-private partnership to advance the development of new health technologies for the developing world The Global Health Innovative Technology Fund (GHIT Fund) has officially launched. The GHIT Fund has been established to advance the R&D of new medicines, vaccines and diagnostics to fight infectious diseases in the developing world.

More... »

Sanford Heisler files $100m+ class action complaint against Daiichi Sankyo

Wednesday, February 13, 2013 10:32 AM

Six current and former female pharmaceutical sales professionals have filed a $100 million class and collective action gender discrimination lawsuit against Daiichi Sankyo, the U.S. branch of the Japan-based pharmaceutical company, in the U.S. District Court for the Northern District of California.

More... »

Daiichi Sankyo, Amplimmune to develop AMP-110 therapy for autoimmune disease

Wednesday, January 9, 2013 10:42 AM

Japan-based Daiichi Sankyo and Amplimmune, a Gaithersburg, Md.-based developer of novel co-stimulatory/co-inhibitory molecules that rebalance the immune system,  have entered into a broad strategic collaboration to develop a new therapeutic protein, AMP-110 (B7-H4 fusion protein). 

More... »

AMRI and Biota strike development and manufacturing deal

Wednesday, April 18, 2012 09:44 AM

AMRI, a global contract research and manufacturing organization, was selected by Biota Holdings, an Australian anti-infective drug development company, to further develop and manufacture influenza antiviral CS8958 (laninamivir), a second-generation, long-acting neuraminidase inhibitor.

More... »

Syndax appoints Pappas to board of directors

Friday, April 6, 2012 03:26 PM

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company based in Waltham, Mass., has added Arthur M. Pappas to the ranks of its board of directors.

More... »

Daiichi forms diabetes alliance with NGM Biopharma

Friday, March 30, 2012 03:07 PM

Tokyo-based Daiichi Sankyo has formed a partnership with San Francisco-based NGM Biopharmaceuticals to research and develop new treatments for diabetes.

More... »

Approved: Daiichi Sanyo’s edoxaban

Tuesday, April 26, 2011 01:28 PM

Japan-based Daiichi Sankyo has received marketing approval by the Japanese Ministry of Health, Labor and Welfare for its anticoagulant edoxaban, according to Pharma Times.  

More... »